ghk-cu angiogenesis cancer risk Angiogenic signaling pathways and anti-angiogenic therapy for ghk-cu angiogenesis cancer risk Biological

Under PCAC review for cerebral ischemia, migraine, and trigeminal neuralgia

Use GHK-Cu if tolerability or skin reactivity is the limiting factor, or add it to a retinol regimen as a morning complement targeting dermal density and antioxidant support

Loading phase protocol (acute injury or initial treatment): Dose: 500 mcg to 1 mg per injection Frequency: Once daily Duration: 7 to 10 days Injection site: Subcutaneous, ideally near the area of concern Timing: Morning or evening, consistency matters more than specific time Maintenance phase protocol: Dose: 500 mcg to 1 mg per injection Frequency: 2 to 3 times per week Duration: 4 to 8 weeks total protocol length Cycle recommendation: 2 months on, 2 months off Unlike traditional BPC-157 acetate, which is often administered twice daily due to its shorter half-life, the enhanced stability of the arginate form typically allows for once-daily dosing during the loading phase

Mangano NG et al